|
|
Post by winstonsmith on Mar 25, 2020 19:16:40 GMT -5
I haven't been around much lately so if this has already been addressed please let me know where to find it.
Do we think that all this new capital available from the stimulus bill will make funds available to Mannkind? Could it be that all of a sudden money that was unavailable to Mannkind is suddenly available and cheap? Thoughts?
|
|
|
|
Post by seanismorris on Mar 25, 2020 19:48:14 GMT -5
MannKind is certainly looking for free money... MannKind has initiated a collaboration with Immix Biopharma, Inc. recently to refocus pipeline resources in response to COVID-19 pandemic. The problem is MannKind isn’t shy about putting out B.S. PR. Remember in 2016/17 when MannKind was ‘aggressively’ moving forward with inhaled epinephrine? MannKind doesn’t even have a pipeline page on its website anymore. To find where it’s supposed to be go to www.mannkindcorp.com/pipeline which will give a 404 error (not important) then click on R&D and pipeline. All you’ll find is ‘rebranding’... |
|
|
|
Capital
Mar 25, 2020 23:57:43 GMT -5
Post by winstonsmith on Mar 25, 2020 23:57:43 GMT -5
BS PR? Nah that's not their style and there are companies that do much of this on a regular basis. Going back 4 years to find something that didn't pan out the way they had hoped...I'm OK with that.
|
|
|
|
Post by seanismorris on Mar 26, 2020 0:30:18 GMT -5
BS PR? Nah that's not their style and there are companies that do much of this on a regular basis. Going back 4 years to find something that didn't pan out the way they had hoped...I'm OK with that. Remember when they described their pipeline potential as an “embarrassment of riches”? Going back 4 years? That’s nothing compared to how long I’ve been here... (like many) You can look through MannKinds press releases. Most of what you’ll see is refinancing debt, presenting at such-and-such conference, and new executives or board members joining the company... opps I forgot the rebranding. MannKind has one product (Afrezza) and one real partner (United Therapeutics). Anyone heard from One Drop? That had quite the buzz for a while. I thought GoodRx would amount to something, but marking was nonexistent... We could create a long list of things that haven’t panned out. If you find the pipeline page (that no longer exists) that would be a good start. My personal favorite for B.S was MannKind partnering with Torrey Pines Institute. Al was so excited about that one, we got zero info on why that went no where... |
|
|
|
Post by matt on Mar 26, 2020 7:45:37 GMT -5
I haven't been around much lately so if this has already been addressed please let me know where to find it. Do we think that all this new capital available from the stimulus bill will make funds available to Mannkind? Could it be that all of a sudden money that was unavailable to Mannkind is suddenly available and cheap? Thoughts? Congress has not made many of the details publicly available, but most stimulus bills of this type focus on preserving existing jobs that would otherwise be lost due to an unexpected decline in business (i.e. auto manufacturers). So far at least, the script numbers seem to be holding up suggesting that MNKD's business, however humble it may be in size, is largely unaffected by recent events. During the last downturn in 2008, virtually no money flowed to the biotech sector to support R&D intensive companies. So this magic pile of money is unlikely to suddenly shower dollars down upon MNKD. It is also important to remember that this is a presidential election year. Companies with heavy employment can deliver votes in November, and doubly so those in "blue" states with unionized operations, and any company with large operations in the "purple" swing states that count most in elections. While that may seem excessively cynical go back to 2008 and look at where the big dollars went, and look at the accompanying legislative changes (such as allowing loss carrybacks if a company goes bankrupt) that were done as political favors. TARP money was made available when the capital markets got tight, but those funds were certainly not cheap and they came with lots of strings. Distressed debt is never cheap. |
|
|
|
Post by brentie on Mar 26, 2020 9:34:43 GMT -5
BS PR? Nah that's not their style and there are companies that do much of this on a regular basis. Going back 4 years to find something that didn't pan out the way they had hoped...I'm OK with that. Remember when they described their pipeline potential as an “embarrassment of riches”? Going back 4 years? That’s nothing compared to how long I’ve been here... (like many) You can look through MannKinds press releases. Most of what you’ll see is refinancing debt, presenting at such-and-such conference, and new executives or board members joining the company... opps I forgot the rebranding. MannKind has one product (Afrezza) and one real partner (United Therapeutics). Anyone heard from One Drop? That had quite the buzz for a while. I thought GoodRx would amount to something, but marking was nonexistent... We could create a long list of things that haven’t panned out. If you find the pipeline page (that no longer exists) that would be a good start. My personal favorite for B.S was MannKind partnering with Torrey Pines Institute. Al was so excited about that one, we got zero info on why that went no where... Not zero but close to it.This is what we heard about Torrey Pines... "Torrey Pines was an opportunity we could not pursue at this time due to program risk, high costs and prolonged timelines." www.mannkindcorp.com/Collateral/Documents/English-US/MNKD%202%203%2016%20Investor%20Call%20FAQ%20v2%209%2016%20FINAL.pdf |
|
|
|
Capital
Mar 26, 2020 12:01:46 GMT -5
Post by winstonsmith on Mar 26, 2020 12:01:46 GMT -5
I haven't been around much lately so if this has already been addressed please let me know where to find it. Do we think that all this new capital available from the stimulus bill will make funds available to Mannkind? Could it be that all of a sudden money that was unavailable to Mannkind is suddenly available and cheap? Thoughts? Congress has not made many of the details publicly available, but most stimulus bills of this type focus on preserving existing jobs that would otherwise be lost due to an unexpected decline in business (i.e. auto manufacturers). So far at least, the script numbers seem to be holding up suggesting that MNKD's business, however humble it may be in size, is largely unaffected by recent events. During the last downturn in 2008, virtually no money flowed to the biotech sector to support R&D intensive companies. So this magic pile of money is unlikely to suddenly shower dollars down upon MNKD. It is also important to remember that this is a presidential election year. Companies with heavy employment can deliver votes in November, and doubly so those in "blue" states with unionized operations, and any company with large operations in the "purple" swing states that count most in elections. While that may seem excessively cynical go back to 2008 and look at where the big dollars went, and look at the accompanying legislative changes (such as allowing loss carrybacks if a company goes bankrupt) that were done as political favors. TARP money was made available when the capital markets got tight, but those funds were certainly not cheap and they came with lots of strings. Distressed debt is never cheap. There is one difference, the new collaboration with Immix to address disorders related to the virus. This could be the key to unlocking those funds. Thoughts? |
|
|
|
Post by falconquest on Mar 26, 2020 12:32:07 GMT -5
Congress has not made many of the details publicly available, but most stimulus bills of this type focus on preserving existing jobs that would otherwise be lost due to an unexpected decline in business (i.e. auto manufacturers). So far at least, the script numbers seem to be holding up suggesting that MNKD's business, however humble it may be in size, is largely unaffected by recent events. During the last downturn in 2008, virtually no money flowed to the biotech sector to support R&D intensive companies. So this magic pile of money is unlikely to suddenly shower dollars down upon MNKD. It is also important to remember that this is a presidential election year. Companies with heavy employment can deliver votes in November, and doubly so those in "blue" states with unionized operations, and any company with large operations in the "purple" swing states that count most in elections. While that may seem excessively cynical go back to 2008 and look at where the big dollars went, and look at the accompanying legislative changes (such as allowing loss carrybacks if a company goes bankrupt) that were done as political favors. TARP money was made available when the capital markets got tight, but those funds were certainly not cheap and they came with lots of strings. Distressed debt is never cheap. There is one difference, the new collaboration with Immix to address disorders related to the virus. This could be the key to unlocking those funds. Thoughts? Not to be too cynical BUT......is this a strategy on the part of Mannkind to align themselves in the COVID-19 fight simply for government money? |
|
|
|
Post by winstonsmith on Mar 26, 2020 14:57:31 GMT -5
There is one difference, the new collaboration with Immix to address disorders related to the virus. This could be the key to unlocking those funds. Thoughts? Not to be too cynical BUT......is this a strategy on the part of Mannkind to align themselves in the COVID-19 fight simply for government money? It's a brilliant strategy IMO regardless if they reach fruition with the treatment or not. Is it ethical to feign a collaboration in order to have access to government funding? No and I don't think that's the case here. |
|
|
|
Post by itellthefuture777 on Mar 27, 2020 7:50:11 GMT -5
The company is looking at ARDS which is the cause of death in Covid-19. ARDS happens from an inflamed lung which then causes fluids and pus to ooze into the alveoli cutting off oxygen transfer through the lung to the blood and vise versa doesn't allow carbon dioxide out of the blood. Inhaled is the method of choice to treat to target..inhaled insulin has shown to reduce lung inflammation...thus the thought is to mitigate risk of death by reducing or eliminating ARDS in Covid-19..so..look it up..the data is out there..I am surprised the Gov hasn't given Mannkind $10 Billion to produce already..
|
|
